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Purpose: Hypoxia-inducible factor-1 (HIF-1 ) primarily α α
mediates the hypoxic response. HIF-1 induction by various α
stimuli contributes to cell proliferation and survival. To in-
vestigate the effect of HIF-1 , we used small interfering RNA α
(siRNA), and expected that cell apoptosis and sensitivity to
chemotherapeutic drug increase, when we blocked the HIF-1α
gene. Thus we performed in vitro and in vivo experiment to
clarify the effect of hypoxia-inducible factor-1 on tumor α
growth. Materials and Methods: We made control and HIF-1α
siRNA using vector plasmid and then transfected Mia-paca
cell lines with these RNAs. After selection with geneticin, two
new cell lines were made, confirmed via immunoblotting.
After treating with gemcitabine, each cell line was assayed to
confirm the effect of HIF-1 siRNA using the cell prolifera α -
tion assay and capase-3 assay. And then in vivo study was
performed using female athymic nude mice. After subcutaneously
injecting each new cell lines, intraperitoneal gemicitabine
chemotherapy was performed for 3 weeks. During that period,
we analyzed the difference of tumor growth rate. Results: The
tumor growth of HIF-1 siRNA-transfected group was slower α
than that of the control group both in vitro and in vivo
experiment. Conclusion: The suppression of HIF-1 results in α
decrease of cell proliferation and increase of chemosensitivity
of pancreatic cancer cell line. Therefore, targeting the HIF-1α
may be useful treatment modality for some pancreatic cancers.
Key Words: Hypoxia-Inducible Factor 1 alpha, small inter-
fering RNA-pancreatic neoplasms
INTRODUCTION
Hypoxia-inducible factor-1 (HIF-1) primarily
mediates the hypoxic response. Since discovered
in 1992, more than 60 genes have been found to
be induced by HIF-1.
1 These genes are related
with cell survival, cell proliferation, apoptosis and
angiogenesis.
2 The human HIF-1 is composed of
two subunits: HIF-1 and HIF-1 . HIF-1 is α β α
undetectable in normoxia condition, but HIF-1 is β
found under oxygen condition. HIF-1 is located α
on chromosome 14 (14q21-4) and HIF-1 is on β
chromosome 1 (1q21). HIF-1 is very labile in α
normoxia with a half-life of less than 5 minutes.
The rapid degradation of HIF-1 is blocked under α
hypoxic condition.
3 Therefore, hypoxia increases
the levels of HIF-1 in cells. HIF-1 induction by α α
various stimuli contributes to the cell proliferation
and survival.
To investigate the effect of HIF-1 , we used RNA α
interference technology using small interfering
RNA (siRNA). siRNA is one of the latest methods
of sequence-specific gene silence. It is a time-effective
means to manipulate gene expression and to probe
gene functions.
4 It was discovered in 1998 and used
to silence gene expression. siRNA can chemically
be synthesized or expressed from vectors transcri-
bing short double stranded hairpin- like RNAs
that are processed into siRNAs inside the cells.
5
Therefore, when HIF-1 gene was blocked with α
HIF-1 -siRNA, we expected the increase of cell α
apoptosis and sensitivity to chemotherapeutic
drug. In the present study, we performed in vitro
and in vivo experiments to clarify the effect of
HIF-1 on tumor growth using siRNAs and a α
chemotherapeutic drug.
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MATERIALS AND METHODS
Cell culture
MIA PaCa-2 cells were grown in Dulbecco's
modified Eagle’s Medium (DMEM, Mediatech,
Herndon, VA, USA), supplemented with 4 mM
glutamine, 1 mM Na-pyruvate, and 10% fetal
bovine serum (FBS), at 37°C in a humidified
atmosphere containing 5% CO2. The cells were
plated (1.5 × 10
5 cells/well, 95% confluent) in 6-
well plates, one for immunoblotting and one for
stable cell line. The following day, confluent cells
were transfected by using the lipofectamine
TM
2000 transfection reagent (Invitrogen, Carlsbad,
CA, USA) following the manufacturer’s instructions
for siRNA of control and HIF-1 . After 48 hours α
of incubation, one each well of transfected cells
was harvested for immunoblotting. Other each
well of transfected cells was selected in DMEM
with the addition of G418 sulfate (Geneticin;
Mediatech, Herndon, VA, USA). The selection was
continued for 3 weeks with 2 mg/mL geneticin.
siRNA preparation
The HIF-1 mRNA specific RNA oligonucleotides α
with 3’-TTTTT overhangs were constructed. The
corresponding RNA oligonucleotides, and the
forward and reverse chains of each gene were
chemically synthesized. We cloned siRNA via
splicing pSilencer 2.1-U6 neo vector plasmid
(Ambion Inc., Austin, TX, USA).
Immunoblotting
Cells of one well were washed with ice-cold
PBS and were resolved in a mixture of 50 mM
HEPES, 50 mM NaCl, 5 mM EDTA, 10 mM
Na2P2O7·10H2O, 50 mM NaF, 1 mM NaVO4, 1%
Triton X-100, and protease and phosphatase inhi-
bitors (Complete mini, Roche Molecular Biomedical,
Indianapolis, IN, USA). The cell lysates were
incubated on ice for 30 minutes, centrifuged for 15
minutes at 3000 rpm and 4°C, and the clear solution
was sonificated for 15 seconds and then kept
frozen (-79°C) until use. Protein concentrations of
the resulting solutions were determined using
Bio-Rad protein assay kit. The extracts were
boiled with sample buffer, and then resolved on
SDS-PAGE gels and then transferred to PVDF
membrane. After blocking in phosphate saline
buffer containing a mixture of 0.2% Tween and
5% dried milk, the blot was probed with a
suitable antibody for HIF-1 (BD Biosciences, San α
Jose, CA, USA). After probing with second
antibody, ECL Plus western blotting detection
(Amersham Biosciences, Piscataway, NJ, USA)
was performed for detection by chemilumine-
scence and chemifluorescence.
Cell proliferation assay
We used MTS ([3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetr
azolium, inner salt]) for cell proliferation assay
and crystal violet assay to detect the effect of drug
sensitivity. Each stable cell line was plated in two
96 wells plates. And then, we treated the cells with
two concentrations (127 mol/L and 254 μ mol/L) μ
of gemcitabine (Eli Lilly Co., Indianapolis, IN,
USA). And then one plate was placed under
hypoxic condition for 2 days. For hypoxia, cells
were incubated at 37°C in 5% mol/mol carbon
dioxide, 1% mol/mol oxygen, and 94% nitrogen
atmosphere, a MTS assay were then performed
using Celltiter96 aqueous one solution (Promega
Co., Madison, WI, USA) following the manufac-
turer’s instructions. Then, crystal violet assay was
performed to confirm MTS assay.
Caspase-3 assay
To examine the basal caspase-3 activities, the
cell pellets from each cell line at 80% confluence
were collected and lysed with the lysis buffer
containing 10 mM Tris-HCl (pH 7.5), 10 mM
NaH2PO4/NaHPO4 (pH 7.5), 130 mM NaCl, 1%
Triton X-100, and 10 mM Na2P2O7 10 H2O. Caspase
activity in the cell lysates was examined according
to a standard protocol (Bio-Rad Laboratories,
Hercules, CA, USA) using substrates specific for
caspase-3-like (Ac-DEVD-AFC), which detects
activity of caspase-3. The intensities were
measured by a fluorescence microplate reader
(Bioteck FL600 Fluorometer, Winooski, VT, USA).
RFUs were standardized to RFU/ g or RFU/10 μ g μ
protein. For each experiment, control groups withEffect of HIF-1 siRNA on Pancreas Neoplasm α
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specific caspase inhibitors, including caspase-3
inhibitor (Z-DEVD-CHO; BD PharMingen, San
Diego, CA, USA), were included to ensure
specificity of the assay.
Animal experiment
Female athymic NCR nu/nu mice (weighing 20
to 23 g; National cancer institute, Frederick, MD,
USA) were acclimatized for 2 weeks in a sterile
environment. Each cell line (2.5 × 10
6 cell/mice)
was subcutaneously injected into tissue of the
back. Both cell lines were injected into same
mouse; control siRNA transfected cells into the
left back and HIF-1 siRNA transfected cells into α
the right back. The tumor cells were allowed to
grow for 1 week. And mice were randomly
assigned to either treatment or the control group.
Five mice for each group were assigned.
Treatment of mice with gemcitabine was carried
out for 21 days by 2 days interval of intra-
peritoneal injection (120 mg/kg). A mice were
daily inspected, and tumor size was measured.
Fifty days after tumor injection, the mice were
sacrificed for collection of tumors. The collected
tumors were frozen and stained with HIF-1 for α
immunofluorescence. And the remnant tumors
were blotted after extraction of proteins. All authors
were authorized from Division of Animal Resource,
Emory University and this animal experiment was
also performed under the permission of Division
of Animal Resource, Emory University. Same
experiment was performed twice.
Statistical analysis
The differences between the groups were con-
sidered statistically significant if the p value was
less than 0.05. The analyses were performed using
z-test of rate ratio.
RESULT
Down regulation of HIF-1 expressions by siRNA α
The expressions of HIF-1 were determined by α
Western blot analysis. As shown in Fig. 1, HIF-1α
siRNA decreased the expression of HIF-1 . The α
effect of siRNA was amplified in hypoxic condi-
tions.
Differences in inhibition of cell growth by
chemotherapeutic drug
Cell proliferation assay of control and HIF-1α
siRNA transfected MIA paca-2 cell lines treated
with two concentrations of gemicitabine showed
that the growth of HIF-1 siRNA transfected MIA α
paca-2 cell line was more susceptible to gemici-
tabine than that of control siRNA transfected MIA
paca-2 cell lines. (p = 0.047, z = 1.667) (Fig. 2) We
also confirmed the result by crystal violet assay.
Caspase-3 assay revealed that caspase-3 activity
was more increased in HIF-1 siRNA transfected α
MIA paca-2 cell line than in control siRNA
transfected MIA paca-2 cell lines. And similar
results were also obtained in gemicitabine and
hypoxia groups (Fig. 3).
Fig. 1. Western blottings of control (C) and HIF-1 (H) α
siRNA transfected MIA paca-2 cell line in normoxia and
hypoxia condition show that HIF-1 expression was α
suppressed in siRNA transfected MIA paca-2 cell line.
Fig. 2. Cell proliferation assay of control (C) and HIF-1α
(H) siRNA transfected MIA paca-2 cell lines treated with
gemicitabine (G1: 127 mol/L, G2: 254 μ mol/L) show that μ
HIF-1 (H) siRNA transfected MIA paca-2 cell line is more α
susceptible to gemicitabine, especially under hypoxia (h).Lily Yang and Won-Kyung Kang
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Differences in tumor growth of mice experiment
Tumor growth of control and HIF-1 siRNA α
transfected MIA paca-2 cell lines showed that the
growth of HIF-1 siRNA transfected MIA paca-2 α
cell line was slower than that of control siRNA
transfected MIA paca-2 cell lines. Also, tumor
growth of control and HIF-1 siRNA transfected α
MIA paca-2 cell lines treated with gemicitabine
showed that the growth of HIF-1 siRNA α
transfected MIA paca-2 cell line was more
susceptible to gemicitabine than that of control
siRNA transfected MIA paca-2 cell lines (p = 0.044,
z = 1.825)(Fig. 4).
Finally immunofluorescence staining of resected
tumor from mice confirmed that the HIF-1α
siRNA activity was still effective in mice (Fig. 5).
DISCUSSION
Pancreas cancer remains as an aggressive
neoplasm, and survival of patients is still
measured in months. It is responsible for almost
6% of all cancer-related deaths.
6 Currently, 5-FU
and gemicitabine are the main agent of chemo-
therapy. Gemicitabine is a deoxycytidine analogue
with structural and metabolic similarities to
cytarabine. Because the reported response rate is
Fig. 3. Caspase-3 activity is increased more in HIF-1α
siRNA transfected MIA paca-2 cell line (H) than in control
siRNA transfected MIA paca-2 cell lines (C). Similar results
were also observed in gemicitabine (G) and hypoxia (h)
groups.
Fig. 4. Difference in tumor growth of control (C) and HIF-1
(H) siRNA transfected MIA paca-2 cell lines treated with α
or without gemicitabine (G: 120 mg/kg), showing that
HIF-1 (H) siRNA transfected MIA paca-2 cell line is α
slower than that of control and siRNA transfected MIA
paca-2 cell lines.
Fig. 5. Immunohistofluorescence of tumor in each group of
mice treated with gemicitabine to confirm HiF-1 inhibi α -
tion. HiF-1 (H) siRNA transfected tumor shows less α
cellularity than control (C) (× 100).
C
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less than 30% and the toxic effects may be
significant,
7 we attempted to find increase the
chemosensitivity and the effect of gemicitabine.
HIF-1 primarily mediates the hypoxic response.
Since its discovery, more than 60 genes have been
found to be induced by HIF-1.
1 These genes are
associated with cell survival, cell proliferation,
energy metabolism, apoptosis and angiogenesis.
2
The human HIF-1 is composed of two subunits:
HIF-1 and HIF-1 . HIF-1 is undetectable in α β α
normoxia condition, but HIF-1 is found under β
oxygen condition and persistantly expressed.
HIF-1 is located on chromosome 14 (14q21-4) α
whereas HIF-1 is on chromosome 1 (1q21). HIF-1 β
is very labile in normoxia with a half-life of less α
than 5 minutes. The rapid degradation of HIF-1α
is blocked in hypoxic condition. Therefore,
hypoxia increases the levels of HIF-1 in cells. α
HIF-1 induction by various stimuli contributes to α
cell proliferation and survival. Therefore, HIF-1 is
a pivotal transcriptional factor in the cellular
response to hypoxia. In malignant glioma, over-
expression of HIF-1 induced by hypoxia is α
essential event in the activation of glioma cell
motility through alteration of invasion-related
molecules such as metallloproteinase -2 or 9.
8 Also
HIF-1 is activated by non-hypoxic stimuli through
activation of diacylglycerol-sensitive protein
kinase-C pathway.
9,10 On the other hand, activation
of HIF-1 by non-hypoxic activator seems to be a
cell-type specific response. Induction of HIF-1 by
growth factors (insulin-like growth factor-2,
epidermal growth factor) contributes to autocrine
solicitation of proliferation and survival.
1
Therefore, the downregulation of HIF-1 in cancer
cells could have important effects on tumor
growth. Many inhibitors of HIF-1 activity are
currently under clinical trials.
1
In this study, we tried to knock-down HIF-1 α
by using siRNA technique, since siRNAs are one
of the most recent molecules used to silence gene
expression and currently widely used as nucleic
acid-based sequence-specific gene silencing mole-
cules.
11 siRNAs found in nature are derived from
cytoplasmic processing of dsRNA by the RNase-
III-type enzyme termed dicer. siRNAs can also be
chemically synthesized or expressed by vectors
transcribing short double-stranded hairpin-like
RNAs that are processed into siRNAs inside the
cell.
5,12 The HIF-1 siRNA used in the present α
study was chemically synthesized with RNA
oligonucleotides and cloned with splicing vector
plasmid.
13 Although they did not completely
knock-out, we successfully made a new cell lines
and confirmed its effectiveness was confirmed by
many immunoblotting assays. We confirmed that
knock-out of HIF-1 decreased the tumor growth α
and increased the response rate of gemicitabine in
vitro and in vivo studies.
Several cellular steps are required to activate
HIF-1, including accumulation of HIF-1 protein, α
nuclear translocation, formation of HIF-1 complex
with HIF-1 protein, and binding to DNA. β
Among these 4 steps, the accumulation of HIF-1α
protein in hypoxia is considered to be a key step
for the transcriptional activation of HIF-1.
14
Introduction of HIF-1 targeted siRNA results in α
downregulation of HIF-1 . Therefore, the inhibition α
of tumor growth results from the decrease of
cellular responses to HIF-1 . α
8
The presence of hypoxic regions in solid tumors
is a common phenomenon and results in dramatic
alterations in gene expression.
15 And hypoxic
condition may be more similar to in tumor-in-situ
than normoxia. Therefore, we explored whether a
hypoxia environment could affect HiF-1α
expression and tumor growth. In this study, the
effect of HIF-1 siRNA was found to be more α
remarkable than normoxia under the hypoxic
condition.
The next research project should be how to
deliver the siRNA to tumor-in-situ like 2ME2,
inhibitor of HIF-1 activity.
1 Furthermore, the
methodology of knock-out of HIF-1 using siRNA α
can be used in other neoplasms.
Although the gene expression of HIF-1 may be α
confirmed at protein and RNA levels, the sup-
pression of HIF-1 by the use of siRNA technique α
results in decrease of cancer cell proliferation and
increase of chemo-sensitivity. Consequently,
targeting the HIF-1 to inhibit tumor growth may α
be useful in treatment of some pancreas neoplasms.
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